Termination Notice (Form 15-12B)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36841

INOVALON HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

4321 Collington Road

Bowie, Maryland 20716

(301) 809-4000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Class A Common Stock, $0.000005 par value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

	Rule 12g-4(a)(1)		☒
	Rule 12g-4(a)(2)		☐
	Rule 12h-3(b)(1)(i)		☒
	Rule 12h-3(b)(1)(ii)		☐
	Rule 15d-6		☐
	Rule 15d-22(b)		☐

Approximate number of holders of record as of the certification or notice date:

Class A Common Stock: One (1)*

*

On November 24, 2021, pursuant to an Agreement and Plan of Merger, dated as of August 19, 2021, by and among Inovalon Holdings, Inc., a Delaware corporation ("Company"), Ocala Bidco, Inc., a Delaware corporation ("Parent"), and Ocala Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). At the closing, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as the surviving corporation and as a wholly owned subsidiary of Parent.

Pursuant to the requirements of the Securities Exchange Act of 1934, Inovalon Holdings, Inc. has duly caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: December 6, 2021			INOVALON HOLDINGS, INC.
		By:		/s/ Keith R. Dunleavy, M.D. Name: Keith R. Dunleavy, M.D. Title: Chief Executive Officer